<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325322</url>
  </required_header>
  <id_info>
    <org_study_id>16-010521</org_study_id>
    <nct_id>NCT03325322</nct_id>
  </id_info>
  <brief_title>Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease</brief_title>
  <official_title>Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal&#xD;
      stem/stromal cell function, kidney function, markers of inflammation, and physical function&#xD;
      in individuals with advanced chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal&#xD;
      stem/stromal cell function, kidney function, markers of inflammation, and physical function&#xD;
      in individuals with advanced chronic kidney disease, particularly diabetic kidney disease.&#xD;
      This study will involve a single 2-day oral treatment regimen with fisetin or placebo. Study&#xD;
      subjects will be randomized 2:1 to study drug or placebo. Study visits will consist of blood,&#xD;
      urine, and abdominal wall skin and subcutaneous fat samplings in addition to testing of&#xD;
      physical strength at given time points. Subjects will be followed for a total of 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory markers including C-reactive protein</measure>
    <time_frame>14 days</time_frame>
    <description>To examine the effect of study drug (compared to placebo) on markers of inflammation in skin, fat, plasma, and urine measured at baseline and day 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on Mesenchymal stem cell function including cell migration</measure>
    <time_frame>14 days</time_frame>
    <description>To examine the effect of study drug (compared to placebo) on mesenchymal stem cell function and vitality measured at baseline and day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on measures of Frailty including Fried Criteria</measure>
    <time_frame>4 months</time_frame>
    <description>To examine the effect of study drug (compared to placebo) on markers of physical frailty (frailty phenotype).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function including estimated glomerular filtration rate</measure>
    <time_frame>4 months</time_frame>
    <description>To examine the effect of study drug (compared to placebo) on kidney function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function including urine protein excretion rate</measure>
    <time_frame>4 months</time_frame>
    <description>To examine the effect of study drug (compared to placebo) on kidney function protein excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events including hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety and tolerability of study drug taken over two days (compared to placebo)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fisetin 20 mg/kg/day, orally for 2 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules orally for 2 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>Flavonoid family</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-80 years&#xD;
&#xD;
          -  Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73m2&#xD;
&#xD;
          -  For the diabetic kidney disease (DKD) subgroup: Diabetes mellitus (on medication)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin A1c&gt;11% at screening for the DKD subgroup&#xD;
&#xD;
          -  Body weight &gt;150 kg or body mass index&gt;50&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active glomerulonephritis treated with immunosuppressive therapy&#xD;
&#xD;
          -  Solid organ transplantation (eg. kidney, pancreas, liver, lung, heart)&#xD;
&#xD;
          -  Active immunosuppression therapy&#xD;
&#xD;
          -  History of active substance abuse (including alcohol) within the past 2 years,&#xD;
&#xD;
          -  Current alcohol abuse (&gt;3 alcoholic beverages/day or &gt;21 per week),&#xD;
&#xD;
          -  Human immunodeficiency virus infection&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  Total bilirubin &gt;2x upper limit of normal&#xD;
&#xD;
          -  Uncontrolled psychiatric disorder&#xD;
&#xD;
          -  Uncontrolled systemic lupus erythematosus&#xD;
&#xD;
          -  Uncontrolled pleural/pericardial effusions or ascites&#xD;
&#xD;
          -  New invasive cancer except non-melanoma skin cancers&#xD;
&#xD;
          -  Invasive fungal or viral infection&#xD;
&#xD;
          -  Inability to tolerate oral medications&#xD;
&#xD;
          -  Known hypersensitivity or allergy to Fisetin&#xD;
&#xD;
          -  Subjects taking medications that are sensitive to substrates or substrates with a&#xD;
             narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6CYP2C9, CYP2C19, CYP1A2,&#xD;
             Other (OATP1B1) (Unless willing and able to stop or modify the dosing of the drug) or&#xD;
             strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus).&#xD;
&#xD;
          -  Tyrosine kinase inhibitor therapy&#xD;
&#xD;
          -  Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low&#xD;
             molecular weight heparin, factor Xa inhibitors, etc.).&#xD;
&#xD;
          -  Subjects on full-dose 325 mg aspirin or other anti-platelet agents (eg. clopidogrel)&#xD;
             daily who are unable or unwilling to reduce or hold therapy prior to and during the&#xD;
             2-day drug dosing. Subjects may continue their previous regimen on day 3.&#xD;
&#xD;
          -  Baby aspirin (81 mg), if necessary for cardioprotection, will be allowed but&#xD;
             encouraged to hold.&#xD;
&#xD;
          -  Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold&#xD;
             therapy 2 days prior to and during the 2-day drug dosing. Subjects taking&#xD;
             H2-antagonists and unwilling to discontinue therapy for 2 weeks before and one week&#xD;
             following enrollment. (See Appendix 4)&#xD;
&#xD;
          -  Subjects taking glimepiride or glyburide for diabetes therapy who are unable or&#xD;
             unwilling to reduce or hold therapy prior to and during the 2-day drug dosing.&#xD;
&#xD;
          -  Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals&#xD;
             (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,&#xD;
             erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir,&#xD;
             elbasvir/grazoprevir), Rifampin&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt;450 msec&#xD;
&#xD;
          -  Tobacco use (smoking or chewing; Unless subject willing to reduce use by 50% prior to&#xD;
             and during the study) - see Behavioral Modification information below.&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Presence of any condition that the Investigator believes would put the subject at risk&#xD;
             or would preclude the patient from successfully completing all aspects of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LaTonya J Hickson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Patri, MS, CRC</last_name>
    <phone>507-293-3732</phone>
    <email>patri.justin@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Lawson</last_name>
    <phone>507-255-7975</phone>
    <email>lawson.donna3@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Patri, MS, CRC</last_name>
      <phone>507-293-3732</phone>
      <email>patri.justin@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Donna Lawson</last_name>
      <phone>507-255-7975</phone>
      <email>lawson.donna3@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>LaTonya J. Hickson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Mesenchymal stromal cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

